Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme-Reference-Cited by-同舟云学术

Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

Published:2014-10-08 Issue:5 Volume:115 Page:764-771
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Caffo Orazio¹,De Giorgi Ugo²,Fratino Lucia³,Lo Re Giovanni⁴,Basso Umberto⁵,D'Angelo Alessandro⁶,Donini Maddalena⁷,Verderame Francesco⁸,Ratta Raffaele⁹,Procopio Giuseppe¹⁰,Campadelli Enrico¹¹,Massari Francesco¹²,Gasparro Donatello¹³,Macrini Sveva¹⁴,Messina Caterina¹⁵,Giordano Monica¹⁶,Alesini Daniele¹⁷,Zustovich Fable⁵,Fraccon Anna P.¹⁸,Vicario Giovanni¹⁹,Conteduca Vincenza²,Maines Francesca¹,Galligioni Enzo¹

Affiliation:

1. Medical Oncology Department; Santa Chiara Hospital; Trento Italy

2. Medical Oncology Department; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS; Meldola Italy

3. Medical Oncology Department; National Cancer Institute; Aviano Italy

4. Medical Oncology Department; Santa Maria degli Angeli Hospital; Pordenone Italy

5. Medical Oncology Unit 1; Istituto Oncologico Veneto IOV - IRCCS; Padua Italy

6. Medical Oncology Department; San Vincenzo Hospital; Taormina Italy

7. Medical Oncology Department; Civil Hospital; Cremona Italy

8. Medical Oncology Department; Villa Sofia Cervello Hospital; Palermo Italy

9. Medical Oncology Department; Unicampus University; Rome Italy

10. Department of Radiological, Oncological and Anatomopathological Sciences; La Sapienza; University of Rome; Rome Italy

11. Medical Oncology Department; National Cancer Institute; Milan Italy

12. Medical Oncology Department; Civil Hospital; Lugo di Romagna Italy

13. Medical Oncology; Azienda Ospedaliera Universitaria Integrata; University of Verona; Verona Italy

14. Medical Oncology Department; Civil Hospital; Parma Italy

15. Medical Oncology Department; Santa Maria della Misericordia Hospital; Udine Italy

16. Medical Oncology Department; Papa Giovanni XXIII Hospital; Bergamo Italy

17. Medical Oncology Department; Sant'Anna Hospital; Como Italy

18. Medical Oncology Department; Casa di Cura Pederzoli; Peschiera del Garda Italy

19. Medical Oncology Department; San Giacomo Apostolo Hospital; Castelfranco Veneto Italy

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12857/fullpdf

Reference28 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;Bono;Lancet,2010

4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

5. Abiraterone and increased survival in metastatic prostate cancer;Bono;N Engl J Med,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis;Asia-Pacific Journal of Clinical Oncology;2020-09-05

2. Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome;European Journal of Cancer;2020-04

3. Computational modelling of resistance and associated treatment response heterogeneity in metastatic cancers;Physics in Medicine & Biology;2019-05-23

4. Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study;Urology;2018-03

5. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review;Future Oncology;2018-02